ClinicalTrials.gov
public full text
Public Domain
Everolimus on CKD Progression in ADPKD Patients
The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care#834224
- Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)#279646
- Everolimus in de Novo Heart Transplant Recipients#839170
- Supplemented Low Protein Diet and Progression of CKD#154830
- KNOW-CKD Cohort, Phase II Study#916792
Record · ID 1007249
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive